Xeris Biopharma Holdings Inc (XERS) Expected Move

Tracking the XERS expected move helps you see how far Xeris Biopharma Holdings Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Xeris Biopharma Holdings Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the XERS expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For XERS, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The XERS expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Xeris Biopharma Holdings Inc is unlikely to go.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect.

The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the XERS expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Xeris Biopharma Holdings Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about XERS.